ArticleNeuroImmune pharmacology and therapeutics2026
Methamphetamine enhances HIV infection of human iPSC-derived microglia.
Article in NeuroImmune pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Methamphetamine (METH) is a potent psychostimulant that is commonly used by people infected with HIV. Clinically, METH use is implicated in HIV infection and neuroinflammation. In this study, we examined whether METH has direct effect on HIV infection of human microglia, the major target and reservoir cells for the virus in the brain. We observed that METH treatment of human iPSC-derived microglia (iMg) significantly enhanced HIV replication, as indicated by increased HIV gag expression, p24 protein levels, and reverse transcriptase activity. Mechanistically, METH suppressed the expression of interferons (IFNs), IFN stimulated gene (Viperin) and the CC chemokine (RANTES). In addition, METH upregulated the expression of the HIV entry coreceptors (CCR5 and CXCR4) in iMg. These findings suggest that METH use is a promoting factor for HIV infection of microglia. Because many individuals infected with HIV use METH, it is important to further investigate the interactions between METH use and HIV in target cells to better understand the mechanisms underlying HIV persistence in the brain and to develop effective strategies for viral eradication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.